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PAUL EHRLICH AS A COMMERCIAL SCIENTIST
AND RESEARCH ADMINISTRATOR
by
JONATHAN LIEBENAU *
Historians and biographers have studied Paul Ehrlich as a biochemist, a medical
messiah,andaneccentric.1 ThelinkswithindustryofthisNobelPrize-winningpioneer
ofexperimental therapeutics and immunology have, however, been largely neglected.
Perhaps this was because commercial involvement was regarded as unseemly by
historians, or because those ties were thought to be insignificant in relation to the
major contributions Ehrlich made to therapeutic practice and theory. More recently,
attitudes have changed: Ehrlich's resurrection as a company scientist is almost
complete after a large commemorative exhibition mounted by Hoechst AG and that
company's sponsorship of a major new biography,2 facilitating further analysis of
Ehrlich's commercial work. This paper goes beyond biography to provide an analysis
of an early example ofmedical science as a corporate activity.
INSTITUTIONAL STRUCTURE
Ehrlich's corporate ties became strongest when he directed the Konigliches Anstalt
fur experimentelle Therapie (1896-1915), which became the Paul Ehrlich Institute in
Frankfurt-on-Main. This Institute was a centre offour overlapping groups: academic
medical scientists, practitioners, government officials, and producers of new
therapeutics. Within it, several new medicines were developed or improved, and the
quality and influence of its work quickly elevated it to the stature of the Pasteur
Institute. Butitslinkswith industry differentiated Ehrlich's institute from the Pasteur,
as it became a centre oftheoretical medical science, the official regulator ofsera and
vaccine,andthemostexcitingproduct-development laboratorywell into theinter-war
years.
*Jonathan Liebenau, Ph.D., Lecturer in Information Systems, London School of Economics, Houghton
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The genesis of this institutional development dates from the development of
diphtheria antitoxin, in the 1890s. Antitoxins were produced using a radically new
conceptualization ofthecharacterofdisease-causingagentsandtheability ofthebody
to cope with them. Injecting a medicine made from the blood of a diseased animal
required a totally new attitude to therapy. Although animal extracts ofvarious sorts
had been used as injectables, and vaccines seemed conceptually similar, the processes
involved in the exffraction of antitoxins were based on a novel and unexpected
theoretical structure. Furthermore, there was an element ofmystery in the process of
antitoxin production, uncomfortably reminiscent ofhomeopathic theory.
After three years of chemical tests on the formulation of diphtheria antitoxins,
developed by Emil von Behring and Shibasaburo Kitasato in 1890, a number of
producers worldwide were anxious to manufacture it and the medicines which would
evidently follow.3 Antitoxins were produced in a straightforward manner. The
disease-causing bacillus was grown in cultures and the toxin extracted. The toxin was
theninjectedinincreasingquantities over afewweeksintothehostanimal: firstguinea
pigs and sheep were used, later horses. The animals displayed some symptoms ofthe
disease but remained essentiallyhealthy while theirimmune systemsproduced arising
titreofantitoxins. Someblood wasextracted, allowed toclot, and the serumseparated
out. After being carefully handled and packaged it was injected into the afflicted
person to counteract disease.
The simplicity and promise ofthis procedure created considerableoptimism. Many
diseases were apparently curable in this way. All that was needed was to isolate the
causative agent, extract the toxin, and prepare the therapeutic antitoxin. This
procedure was tried by some experimenters, especially in company laboratories, for
nearly all diseases, leading to the marketing of products. But from an early stage
problems plagued the makers of antitoxins. It seemed impossible to control the
strength of the antitoxin. This could be roughly measured by its volume and by the
amount it took to kill an experimental animal, but such standards were inadequate to
say the least. By developing a satisfactory testing procedure, Paul Ehrlich began the
process of formalizing not only a research programme for his group, but also the
foundation of technical standards for drug regulation.4
Once it was clear that Behring's antitoxin was a marketing success, the
Reichsgesundheitsamt (Ministry of Health) seized the opportunity to impose
regulations. Many physicians were, of course, concerned that this new class of
therapeuticproducts was being put on themarket, and wanted some assurances about
safety, purity, andconsistency. Alreadyby November 1894legislation limitedtheir use
except with aphysician's prescription, through apothecaries. The criteria forapproval
3 E. Behring and S. Kitasato, 'Ueber das Zustandekommen der Diphtherie-Immunitiit und der
Tetanus-Immunitat bei Thieren', Dt. med. Wschr., 1890, no. 49: 1113-14; E. Behring, 'Untersuchungen
uiber das Zustandekommen der Diphtherie-Immunitat bei Thieren', ibid., no. 50: 1145-8.
4 Asidefrom Baumler'sbiography(op. cit., note 2above), a numberofdetailed studieshave added much
to our appreciation of Ehrlich. They include: I. Galdston, 'Some notes on the early history of
chemotherapy', Bull. Hist. Med., 1940, 8: 956-64; J. Parascandola and R. Jasensky, 'Origins of the
receptor theory ofdrug action', ibid., 1974, 48: 199-220; J. Parascandola, 'Carl Voegtlin and the "arsenic
receptor" in chemotherapy', J. Hist. Med., 1977, 32: 151-71; L. P. Rubin, 'Styles in scientificexplanation:
Paul Ehrlich and Svante Arrhenius on immunochemistry', ibid., 1980, 35: 397-425.
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ofantitoxin included an assessment ofits potency, using a method ofassay analysing
the amount necessary to neutralize a given volume of toxin.5 To facilitate this
laboratory work, the Control Station for Diphtheria Antitoxin was established in
1895. Given its task, the appropriate location was alongside Robert Koch's Institute
for Infectious Diseases, in the Charite Hospital in Berlin. Koch assumed the nominal
directorship, but testing was conducted by Drs Hermann Kossel and August von
Wassermann.6
As interest in antitoxin grew worldwide and production increased, the functions of
thetestinglaboratoryattheControl Stationalsoexpanded. By 1895therewerealready
three major commercial producers of antitoxin in Germany: Hoechst, Merck, and
Schering. HoechstandScheringco-operatedandallowedalltheirantitoxintobetested
at the Control Station.7 Soon the logistics ofmaintaining a smooth flow ofproduct
samples through thelaboratorycreatedpressures on space. Furthermore, thecomplex
testing procedures needed constant reassessment. It was clear that new products were
on their way, particularly tetanus antitoxin, which had been developed along with
diphtheriaantitoxin. Moreoverthefunction ofthelaboratory wasillimitable: with the
academic orientation of Kossel and Wassermann, the laboratory was from the start
working towards a theoretical understanding of immunity.8
Because of the large-scale testing functions, as well as the increasing volume of
experimental andtheoreticalwork, andthrough thesympatheticofficesofthedirector
of the Prussian Ministry of Educational and Medical Affairs, Friedrich Althoff, a
larger facility was provided in the Berlin suburb ofSteglitz in 1896 and Paul Ehrlich
wasmadedirector.9 Work at the Steglitz laboratory, whichwascalled the Institute for
5 P. Ehrlich, 'Die staatliche Kontrolle des Diphtherieserums', Berl. klin. Wschr., 1896, no. 20: 441-3.
See also M. J. Rosenau, The immunity unit for standardizing diphtheria antitoxin (based on Ehrlich's
normal serum), Hygienic Laboratory Bulletin 21, Washington, USGPO, 1905.
6G. Siefert, 'Bundesamt fur Seraund Impfstoffe, Paul-Ehrlich-Institute-its structureand scope', Drugs
Made in Germany, 1982, 25: 28-36. See also E. Hickel, 'Das Kaiserliche Gesundheitsamt und die
chemische Industrie im Zweiten Kaiserreich (1871-1918): Partner oder Kontrahenten?', in G. Mann and
R. Winau (eds.) Medizin, Naturwissenschaft, Technik und das Zweite Kaiserreich, G6ttingen,
Vandenhoeck and Ruprecht, 1977.
7 See W. Vershofen, Wirtschafts-geschichte der chemisch-pharmazeutischen Industrie, vol. 3, 1870-1914,
Aulendorf, Cantor, 1958, pp. 29ff. W. Bernsmann, 'Arzneimittelforschung und Entwicklung in
Deutschland in der zweiten Hiilfte des 19. Jahrhunderts', Pharm. Ind., 1967, 29; 1968, 30; Hoechst AG,
Die Zusammenarbeit Behring-Hoechst 1892-1904, vol. 37, Dokumente aus Hoechster Archiven, 1968;
Hoechst AG, Farbwerke vorm. Meister Lucius & Brnming 1863-1913, 1913, p. 29; A. Fiermann, 'Die
Einrichtungen zur Darstellung des Diphtherie-Heil-Serus in den ... Hoechster Farbwerke', Munchener
med. Wschr., 1894, 51: 1038-40, P. Korn, 'Geschichte der bakteriologische Abteilung der Schering AG
1893-1942', MS, Schering AG Archive, Berlin; H. Hollander, Geschichte der Schering Aktiengesellschaft,
Berlin, Schering, 1955, pp. 29ff., 96. File "xc 1.2" Schering Archive: I. Possehl, 'Impfstoffe, Sera,
Diagnostika-Resultate bakteriologischer und immunologischer Forschung', MS, 1983, pp. 6ff. See also H.
Loewe, 'Paul Ehrlich und Emil van Behring in ihren Beziehungen zu den Farbwerke Hoechst',
Arzneimittelforsch., 1954, 4: 1-15.
8p. Ehrlich, H. Kossel and A. von Wassermann, 'Ueber Gewinnung und Verwendung des
Diphtherieheilserums', Dt. med. Wschr., 1894, 16: 155, 237, 293. W. Kolle, 'Das Staatsinstitut fur
experimentelle Therapie und das Chemotherapeutische Forschungsinstitut Georg Speyer-Haus in
Frankfurt a/M, Ihre Geschichte, Organisation und ihre Arbeitsgebiete nebst vollstandigem Verzeichnis
der in den Jahren 1896-1924 veroffentlichen Arbeiten', Arbeiten aus dem Staatsinstitutfuir Experimentelle
Therapie und dem Georg Speyer-Hause zu Frankfurt a/M, 1924, 13: 7ff.; Baumler, op. cit., note 2 above,
p. 57.
9 Ibid., p. 59; Siefert, op. cit., note 6 above.
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Serum Research and Serum Testing, focused increasingly on theoretical problems of
the nature ofimmunity, as well as the technicalities ofstandardizing and testing, and
thelogisticsofcertifyingcommercial preparations. Duringthisperiod, 1896-9, Ehrlich
concentrated hiswork on theestablishment ofan international unit ofantitoxin using
assay techniques which could be easily adopted.'0
Thelaboratory'sconcern toestablishaninternational unitwasreinforced in 1896by
the report of the Lancet's commission on the "Relative Strengths of Diphtheria
Anti-Toxic Serums".'" The Lancet tested antitoxin from the three main German
suppliersandthreeBritishsuppliers, aswellasaFrench,aBelgianandaSwissproduct.
They found large discrepancies between the brands, and levels of potency diverged
widely from those claimed on labels. Ofthe samples tested, those from Schering and
Hoechst wereevidently superior. Ehrlich cited these results as proving the need for an
international standard which was easy to follow and unambiguously enforceable.12
The same article advanced several related arguments. Beginning with the
understanding that "oneofthemain tasks ofthe Instituteis to measurethepotency of
theantidiphtheria seraproducedinGermany", heanalysedthefactorscausingtheloss
ofpotency: water, by hydration; oxygen, by oxidation; light; and heat. The first two
werecontrollable atproduction, and anylossofpotency resulting from themcould be
assessed in the commercial serum, along with standards ofpurity. These assessments
could then be used as a criterion for certification. As a standard he used a desiccated
serum which Behring had produced for him at Hoechst. Further industrial co-
operationwassecuredforprocedures toevacuatetubesfromtheelectriclampworksof
the Allgemeine Elektricitiitsgesellschaft, which "in the most cooperative manner",
wrote Ehrlich, "placed apparatus at our disposal".'3
COMMERCIAL SCIENCE
From the late 1890s, Ehrlich already had partisan feelings towards certain
companies. Some, he believed, were incapable offollowing the necessary procedures
withsufficientcareand"inconsistencies haverepeatedlybeenobservedinthecourseof
dealings" with them.'4Theprocedures whichhe outlined wereofficially confirmedby
an order from Althoff in 1897 and the methods, developed in co-operation with
HoechstandSchering,wereapplicabletotherestoftheindustry.'5 Inordertomeetthe
standards, moreover, manufacturers were to obtain fresh supplies ofstandard toxins
fromEhrlich'slaboratoryabouteverythreeweeks. Suchdependenceworkeddistinctly
in favour of those firms who had produced antitoxins early, and in particular for
Hoechst.
The Hoechst Company had begun modestly, in 1863. A centralized company
laboratory was established in 1883 in a building peripheral to the main plant. The
10Baumler, op. cit., note 2 above, p. 47; see also note 3 above.
1 'Relative strengths of diphtheria anti-toxic serums', Lancet, 1896, ui: 182-96.
12 Paul Ehrlich, 'Die Wertbemessung des Diphtherieheilserums und deren theoretischen Grundlagen',
Klin. J., 1897-8, 6: 135, 155, 167, 234, 292.
13Ibid.
14 Ibid. Translation from The collectedpapers ofPaulEhrlich, ed. P. Himmelweit et al., 3 vols., London,
Perfamon, 1956-60, vol. 3, p. 53.
l Baumler, op. cit., note 2 above, pp. 68-9.
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laboratory director, Dr E. von Gerichten, who held a doctorate in chemistry, was
charged with a variety of tasks arising from the dyestuffs manufacturing process,
including producingnewcolours and testingforconstant quality. Hehad a small staff
of chemists but maintained frequent contact with academic scientists. This staff, in
collaboration with academic workers, exploited opportunities to patent, without
restriction, in Germanyand the United States. By the late 1880s Hoechst already held
many patents on intermediate products and spin-offs from their development
programmes.16
As the academic pharmacology community directed its attention to synthetic
quinine, themain interest at Hoechst turned to the fever-reducing effects ofalkaloids.
Friedrich Stolz, the first full-time pharmacologist in the company laboratory,
developed various alkaloid solutions, finally settling on one preparation which he
called "Pyramidon". In the late 1880s, Pyramidon became a major money-maker for
Hoechst,judgingbothbyitsprominenceincompanydiscussions, andbytheroyalties,
routinely paid to inventors at the firm, which Stolz earned. It provided a strong
incentive to invest in the possibilities of further developments.17
The second major influence on the decision to commit resources to research on
pharmaceuticals was the emphasis on finding a treatment for tuberculosis. Robert
Koch had contacted Hoechst around 1890 about producing Tuberkulin, his anti-TB
agent, and this was seen as amarvellous opportunity to break into ahuge new area of
thedrugbusiness. HesuggestedthatEmilBehringbecontactedaboutapossiblerolein
the development ofTuberkulin and other bacteriologically-based medicines. Behring
hadtocontinue toworkinBerlinuntil 1892,whenhewaspermitted toleavethearmed
forces into which he had been conscripted as a medical officer. When he moved to
Frankfurt to establish Hoechst's antitoxin production programme he found a staffof
somedozenchemists andpharmacists testingdrugs andmonitoring theproduction of
Tuberkulin and Pyramidon.
By the mid-1890s physicians in Germany especially were excited about the promise
ofmedicalscience, andweresearchingfornewproducts. Forthepharmaceutical firms,
theproduction ofnewproducts wasessential forcompetitive advantage. Theindustry
wasgrowingquickly, and themarketswereconstantly beingchallenged. Thebest way
for these firms to distinguish themselves and open new markets was for them to
introducenewmedicines. Thistheydidwithgreatcompetitivezeal,andeverypotential
new product wasimmediately patented. Although relatively few ofthese patents were
developed into the manufacture ofnew drugs, they did delineate areas ofenquiry in
which the company was specializing. The number ofproducts which each firm then
offeredforsaleincreaseddramatically. Despiteagooddealofoverlapamongstandard
medicines on offer, many branded or speciality products were more or less unique to
each firm.'8
16 Jonathan Liebenau, 'Industrial R&D in pharmaceutical firms in the early twentieth century',
Business Hist., 1984, 26: 329-46.
" Ibid. Hoechst AG, Dr. Friedrich Stolz, derErfinderdesPyramidons, vol. 12, Dokumente aus Hoechster
Archiven, 1966; "Friedrich Stolz" file, Hoechst Archive.
18 Hoechst trade catalogues, Hoechst Archive; see also Jonathan Liebenau, 'Patents in the chemical
industry, tools of business strategy', in idem (ed.), The challenge of new technology, Aldershot, Gower,
1988.
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Even while in Berlin, Ehrlich agreed a contract with Hoechst, in March 1894, to
supply diphtheria antitoxin and to be exclusively available to Hoechst for a period of
fifteen years.
The first years of production were highly successful and in 1903 the Hoechst
Company took stock ofits record ofdiphtheria antitoxin production. Close to 20,000
litres had been produced and sold for over 4 million marks, far more than any
competitor.19 In publicizing this record, the company stressed the close collaboration
it had had with Koch, Behring, and Ehrlich.20 In ten years, the production facilities
had grown from being a small offshoot ofthecompany research laboratory under the
personal direction of Behring, to a complex ofbuildings including separate ones for
the production ofTuberkulin, one for most sera and separate stables for the isolation
and treatment of horses used in production. By 1898 the bacteriological laboratory
had also been split off from the pharmaceutical research building, and was the new
centre co-ordinating the production of a wide range ofbiologicals.21
Behring stayed with the company during the period when he was looking for a
professorship. He held one for a short time at Halle, but was offered the position
(over the faculty's objection) as Director of the Hygiene Institute and Professor of
Hygiene at Marburg in 1895.22 He had been with Hoechst for three years, during
which time he set up their antitoxin production. He left acrimoniously, suspicious
that he was being cheated out of some of the profits arising from his efforts, and
would later establish his own company, the Behringwerke in Marburg, to compete
with Hoechst.23
With Koch's Institute for Infectious Diseases and other clinical research
monopolizing hospital space in Berlin, Ehrlich and his team had little opportunity to
conduct controlled bedside trials. As it became clear that facilities at the Steglitz
laboratory were inadequate and a move would be necessary, criteria of a preferred
location were drawn up.24 A large provincial town with ample hospital facilities to
investigate the new experimental therapeutics would be preferable. The general
scientific milieu was also important. Many places might have satisfied these
requirements, but a number of characteristics made Frankfurt-on-Main stand out.
There were a number ofsmall medical research groups there, and particular expertise
in pathology (Carl Weigert), laryngology (Moritz Schmidt-Metzler), and neurology
(Ludwig Edinger)-three areas of special significance for studies of diphtheria and
immunity. Futhermore, there was support from local interests, mobilized by
Frankfurt's Mayor, Franz Adickes. Adickes made funds available for the
construction of the new institute and used his influence among leading
philanthropists to make them favourably disposed towards Ehrlich and his new
venture.25 But the most significant, if less stressed, factor was the proximity of two
19 Annual Report for 1903, Hoechst Archive.
20 Hoechst publicity material, Hoechst Archive.
21 Farbwerke vorm. Meister Lucius & Bruning, op. cit., note 7 above, p. 29; Hoechst Archive.
22 H. Schadewaldt, 'Emil von Behring', DictionaryofScientificBiography, NewYork, Charles Scribner's
Sons, 1971, vol. 1, pp. 574-8.
23 Die Zusammenarbeit, op. cit., note 7 above, pp. 101 ff.
24Baumler, op. cit., note 2 above, pp. 68 ff.
25 Ibid.
70Paul Ehrlich as a commercial scientist
chemical companies with which Ehrlich was already on good terms, Hoechst, just
outside Frankfurt, and Leopold Casella & Co. nearby.
Even before the establishment ofthe Frankfurt Institute in 1899, Ehrlich had had
extensive professional and commercial contacts with Hoechst. In correspondence
with August Laubenheimer, the company's influential advisor and research director,
Ehrlich described much of his work, always sensitive to the possiblity of new
products.26 One clearexample ofthis was his research in 1891 on methylene blue. In
experiments with the nervous system ofanimals, he noticed that the dye distributed
itself selectively within the body. He, and his collaborator, Paul Guttmann, also
found that the dye could be effective against malarial symptoms in instances where
the patient seemed resistant to quinine treatment.27
Ehrlich was always thereafter aware ofthe widest implications ofthis phenomenon
ofselective staining. In 1891 he stated his interest in developing methylene blue into a
major therapeutic agent. "I know", he wrote, "that bacteria work at various sites to
produce different diseases" and that it required much experimentation to make
correlations between location and pathogen, and then furtherexperimentation to find
substances which transmit antibacterial agents to those sites.28 This early work with
methylene blue was one of a number of projects which led to the elaboration of
Ehrlich's side chain theory of immunity. It also resulted in a patented antipyretic
which Hoechst successfully developed and marketed in 1893.29
GOVERNMENT-INDUSTRY LINKS
In 1899 the re-constituted Royal Institute for Experimental Therapy, formed out of
the old Institute for Serum Research and Serum Testing in Steglitz, was established
on a site provided by the city of Frankfurt, adjacent to what later became the
university and the main hospital complex. It was opened by ministerial and local
goverment dignitaries, along with others from nearby universities, hospitals, and, of
course, from the Hoechst company.30 The Hoechst presence was somewhat de-
emphasized by the expedient of listing non-company affiliations for some of its
representatives at the ceremony, perhaps in response to expressed fears that, with
such obvious close ties, the government laboratory would become in effect "das
Institut der Hoechster Farbwerke"..31
The newly-stated functions of the Frankfurt Institute were clearly expressed and
differentiated. Its purposes were, to test all the government-controlled sera; to serve
as a hygiene and bacteriological laboratory to the city, including local hospitals and
26 Hoechst AG, Vorarbeiten zwn Salvarsan, vol. 14, Dokumente aus Hoechster Archiven, 1966; Hoechst
AG, Um die Zubereitung des Salvarsan, 30 Briefe Paul Ehrlichs an Hoechst-Ein Beitrag zur modernen
Galenik, vol. 19, Dokumente aus Hoechster Archiven, 1966.
27 P. Ehrlich and P. Guttmann, 'Ueber die Wirkung des Methylenblaus bei Malaria', Berl. klin. Wschr.,
1891, 39: 420, 483, 506, 551.
28 Ehrlich to Laubenheimer, 1891, Hoechst Archive.
29 Parascandola and Jasensky, op. cit., note 4 above; Antipyrene papers, Hoechst Archive.
30 Walter Greiling, In Banne der Medizin. Paul Ehrlich, Leben und werk, Dusseldorf, Econ, 1954, p. 113.
31 Ibid.
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individual physicians; and to explore the basis of immunology, and in particular
serology, from a theoretical standpoint.32
To be able to integrate these functions, the organization ofthe Institute had to be
complex. The major official function-to test sera and vaccines-was put aside in a
minor department, while whole research groups were devoted to those areas deemed
to be ofthe greatest theoretical interest. By 1905 there were four main departments.
The product-testing department was responsible for setting standards and certifying
products sent to it. The experimental biology department was nominally also
concerned with testing diphtheria antitoxin, but from 1904 was more deeply involved
with general haematology. This again combined two broad functions. On the one
hand, the staffwas meant to conduct tests on behalfofthe public health and medical
authorities in Hesse-Nassau, Rhineland, and Westphalia; on the other, they pursued
their own research along lines directed by Ehrlich into the theory of complement
fixation and into the theory of proteins in combination and their production into
antibodies. Hans Sachs became head of this department. He structured his work
around the side chain theory and most of the experiments there were set up as
assessments ofthe interactions between toxins and antitoxins, or the specific affinities
associated with polyvalent sera.33
The third, so-called "bacteriology and hygiene" department, headed by Albert
Neisser, was conceived as a service sector for Frankfurt hospitals and private
physicians. Most of its work came in through apothecaries who were provided with
sterile kits for physicians to collect sputum suspected ofcontaining diphtheria bacilli
(Klebs-Loeffler). In its early years, the scale of this operation was small compared
with similar services provided by city health departments in New York and
Philadelphia.34 In Frankfurt only one or two samples were tested daily until 1903,
when there was a serious diphtheria epidemic. The number of tests then approached
five daily. More importantly, the department was to organize notification procedures
for the public-health and hospital authorities. Again, in contrast to comparable
operations in the United States, the Institute did not distribute antitoxin directly, but
rather advised the medical profession about which commercial products to use.35
Standard testing for typhus also was introduced in 1903, possibly because in the
period of increased testing during the diphtheria epidemic a large number oftyphus
cases were identified. In the same year, 1903, the number of miscellaneous samples
tested began to increase greatly, so that within a couple of years ten culture analyses
were being performed each day, about a third ofwhich were conducted on behalf of
the city hospitals. In addition, 145 Frankfurt physicians were served, and a smaller
number from surrounding areas. The relationship between the laboratory's functions
32 Kolle, op. cit., note 8 above, p. 10.
33Siefert, op. cit., note 6 above, G. Eissner and G. Heymann, '50 Jahre Chemotherapeutisches
Forschungsinstitut Georg-Speyer-Haus', Arzneimittelorsch. 1956, 9: 501-8; Paul Ehrlich, 'Das
K6nigliche Institut fur experimentelle Therapie zu Frankfurt a/M', in Festschrift z. XIV. Internationaler
Kongress fur Hygiene und Demographie, Berlin, 1907, Medizinische Anstalten auf dem Gebiete der
Volksgesundheitspflege in Preussen, Jena, Fischer, 1907; Kolle, op. cit., note 8 above, pp. 1-60.
34 J. M. Liebenau, 'Public health and the production and use of diphtheria antitoxin in Philadelphia',
Bull. Hist. Med., 1987, 61: 216-36.
35 Kolle, op. cit., note 8 above.
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as a testing facility and as a promoter ofantitoxins was close indeed. In a sense, the
government laboratory was simply unofficially endorsing Hoechst biologicals.36
An additional function became associated with the third department when Neisser
was appointed head ofa training school forpublic health workers in Wiesbaden. This
led to its further involvement with general public health work, including experiments
and tests onwaterandmilk, and aid to thework ofdisinfectors. Even this activitywas
not limited to the public sector, and the laboratory freely certified products and
facilities for private concerns. This busy and outward-looking department also
functioned as a specialized public-health training facility, teaching bacteriology to
government disinfectors, water workers, and others, whileco-ordinatingwith courses
offered elsewhere.37
Moreover, the bacteriology and hygiene department was not divorced from the
theoretical work at the heart of the Institute elucidating the side chain theory. In
this role it served primarily as a source of material for the rest of the Institute, but
Neisser also collaborated on the more theoretical investigations. In addition to his
publications on bacteriological technique and public health, Neisser published (with
Ehrlich's seniorassistant Kiyoshi Shiga) on free receptors in typhus and dysentery-a
central issue for the side chain theory-and defended Ehrlich against Svante
Arrhenius, whose competing agglutination theory had significantly different
implications for research programmes.38
In 1902, along with the general expansion of the Institute's range of activity, a
cancer research section was established. Growing out ofgeneral work on histology, a
large-scale investigation ofcarcinomas inmice was begun. It too was organized under
the general direction of Ehrlich. Its primary technique was to alter the conditions of
tumour transplants to investigate the serial virulence ofcancer cells in recipients and
the response ofthe immune system to foreign bodies. This was a very large-scale and
long-term investigation, involving analytical techniques which were later to becentral
for chemotherapeutic experiments.39
A further function oftheInstitute was to train Frankfurt physicians in new theories
and laboratory techniques. Ehrlich gave weekly lectures on either immunology or
haematology, while Neisser offered a series on either bacteriological techniques or
hygiene and epidemiology. From 1902, when two military surgeons were assigned to
the institute, regular courses on "Kriegshygiene" (military hygiene) were added to the
curriculum.40 Teaching military hygiene was not unique among medical institutions.
The link between medical research and the growing military state was explicitly
expressed in 1907 by the motto embellishing the new wing of the Kaiser Wilhelm
military surgeons' training academy:4'
36 Ibid.
37 Ibid., p. 13; Ehrlich, op. cit., note 33 above, pp. 98-101.
38 M. Neisser and K. Shiga, 'Ueber freie Rezeptoren von Typhus- und Dysenteriebazillen und ueber das
Dysenterietoxin', Dt. Med. Wschr., 1903, 29: 61. See also Rubin, op. cit., note 4 above.
39 Kolle, op. cit., note 8 above, pp. 20-2; Janina Hurwitz, Paul Ehrlich als Krebsforscher, Zurich, Juris,
1962; Ehrlich, op. cit., note 33 above, pp. 101-4. Baumler (op. cit., note 2 above, p. 83) gives 1901 as the
date ofestablishment, but it was not in operation until the next year.
40 Ehrlich, op. cit., note 33 above, p. 102.
41"Pure science/True humanity/Self-sacrificing patriotism". Stabsarzt Dr Ridder, 'Der Neubau der
Kaiser Wilhems-Akademie fur das militararztliche Bildungswesen' in Festschrfit, op. cit., note 33 above.
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REINER WISSENSCHAFT
ECHTER HUMANITAT
OPFERFREUDIGER VATERLANDSLIEBE
For all its differing tasks, the Institute's uniting function was to supervise the
production of sera. In 1906, the first year of the publication of its Arbeiten, the
Institute presented its report to the industry and the medical community on 'The
government tests ofantitoxins'.42 At that time, four products were routinely tested:
diphtheria antitoxins, tetanus antitoxin, tuberculin, and an erysipelas serum of
recent origin. In addition, a variety ofproducts falling into intermediate categories
were analysed for purity. All producers were liable to inspection, and any firm which
wished to introduce a new product into the market had to have it certified by the
Ministry of Health. In order to satisfy the certification requirements, the firms
needed to have a specified number of trained personnel who were required to
maintain strict records of manufacture and sale, and had to submit to other
government controls via the laboratory.43
Ehrlich's work at the Institute was productive and fulfilling. Its three functions of
testing, servicing, and researching operated well, and his staff helped to administer
an efficient laboratory. Ehrlich was, however, concerned about the indiscriminate
impact ofthe Institute and in 1904 he wrote a strong polemic against what he saw as
a great threat to the future ofmedicine. His organization and techniques had led to a
proliferation of products and a loss of the control which he had maintained over
biological medicines. The research front, Ehrlich believed, was moving away from
the unfinished task of producing curative drugs, while manufacturers continued to
offer even longer lists ofproducts.
To the initiate, the lack ofsufficient positive knowledge is revealed by the inactivity
which now characterizes a field once entered upon with so much promise. The
innumerable drugs which have overwhelmed medicine in the past few years, ofwhich
only a few are ofany value and thus denote any real progress, have sufficed speedily
to allay the original enthusiasm. A feeling ofindifference has thus been engendered,
which is constantly being increased by the advertisements which are daily becoming
more and more evident. Apart from these evils, however, this line of study is at
present suffering especially from two other evils:
1) the habit, when a drug has been partly accepted, of immediately following it
with a dozen rivals of similar composition, and
2) the exclusive preference given to drugs acting purely symptomatically, which are
not true curative agents.44
He was not inclined to blame the producers and advertisers of such rivals and
false cures, but rather the dominance ofa chemical, as opposed to the biological and
medical, way of thinking. "A change for the better will occur only when purely
42 Arbeiten aus dem Staatsinstitutfdr experimentelle Therapie, 1906.
43 Ehrlich, op. cit., note 33 above, pp. 92-6.
44 Collectedpapers, op. cit., note 14 above.
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biological points of view are adopted, i.e. if the initiative is transferred from the
chemical to the biological laboratory." This required positive action to recover
control of treatment, and to make theoretical therapeutics a part of practical
medicine. Only thus could physicians be sure that medicine did not become
subordinated to chemistry.
As physicians we must cease to be content with the auxiliary role ofadvisers in these
important questions. In this subject, our very own since time immemorial, we must
insist on taking first place. Now is the time that we must turn to more general,
biological conceptions, and it is therefore the duty ofeveryone to contribute his brick
to the construction of this new therapy.45
Ehrlich's bricks soon took the form ofwalls as he worked toward theestablishment of
a new institute, devoted solely to this programme of research based on biological
conceptions.
One ofthe philanthropists closest to Mayor Adickes was the prominent Frankfurt
Jew, Georg Speyer. Speyer's family had beencity financiers formany generations and
their wealth and seniority within the Jewish community placed them in the central
position among local benefactors.46 Their Foundation was the mainstay for such
institutions as the Jewish orphanage, old-age home, hospital, and cemetery. In 1902,
upon the death ofGeorg Speyer, Franziska Speyer began plans to establish another
medical institution in the city, this one to facilitate research in general medicine47
perhaps alonglines similarto the Rockefeller Institute for Medical Research, founded
that year in the United States. Frau Speyer was sister-in-law to the leading Berlin
chemist, Ludwig Darmstaedter, who in the past had given advice about medical and
scientific philanthropic activities to the Foundation, and sat on its board.48 The
connection with Paul Ehrlich was easily established when Darmstaedter sought him
out.
When Ehrlich, the most prominent medical scientist in the city, made known his
views about the need for a biologically-oriented research programme, Darmstaedter
wasreceptive andconceived aplan forthe Foundation.49 Ratherthancreate ageneral
research institute, Ehrlich wanted to perform a large number of specific tasks. For
him, the most challenging and rewarding medical problems were to be found in
toxicology, pharmacology, and therapeutics. These he conveniently split into the
study and use of such biologically-devised agents as the antitoxins, and such
synthetically-produced drugs as the methylene blue compounds being used as
antipyretics.50
The research methods appropriate to these two kinds of agent were significantly
different, and a separate institution for the sole purpose ofchemotherapeutic research
would also be useful. Ehrlich's wishes were used as a guide in the planning for the
45 Ibid.
46 Speyer papers, Frankfurt Stadtsarchiv; see also Eissner and Heymann, op. cit., note 33 above.
47 Ibid.
48 Ibid.; Baumler, op. cit., note 2 above, chapters 5, 8, 9.
49 Darstaedter's report to Speyer Stiftung, Speyer papers, Frankfurt Stadtsarchiv.
50Ibid.
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Georg Speyer Haus, which opened in 1906. He explained its purpose in the following
way:
Here we shall still be concerned with the problem of curing organisms infected by
certain parasites in such a way that the parasites are exterminated within the living
organism, so that the organism is disinfected, but in this case, not by the use of
protective substances produced by the organism itself through a process of
immunization, but by the use of substances which have had their origin in the
chemists retort. Thus, the task ofthe new institute will be a specific chemotherapy of
infectious diseases. It is easy to see that this line ofapproach, by its very nature, must
be a much more difficult one than that ofserum-therapy. Magic substances like the
antibodies, which affect exclusively the harmful agent, will not be so easily found in
the series of the artificially produced substances.51
The model for even this specific form of programme was already available. Earlier
research on various arsenical-dye anti-trypanosome substances had been supported
by the Bayer Farbwerke, which prepared several hundred specified compounds for
testing.52
In further describing his ambitions for the new laboratory, Ehrlich reconstructed
the intellectual process which had led him to conceive his new programme. Central
was the notion that the distribution of a substance within the body was an issue
different from the specific activity ofthat drug. The empirical task could be split into
the "construction oforganotropic medicaments", and the process ofattaching them
to the appropriate pharmaceuticals. "We intend", he explained, "to use certain
chemical complexes as vehicles to carry appropriate pharmacophore groups to the
desired types of cells".53 Through this process, new products could be conceived
which would contribute to the primary purpose ofsuch a programme: the discovery
of new, rational, curative remedies. And this task, Ehrlich believed, could best be
performed in partnership with the chemical industry "which", Ehrlich stated, "has
devoted its best resources to the service ofmedicine".54
Contacts with Hoechst grew even closer. The new line of research generated a
larger number of substances on which the company could take out patents on
Ehrlich's behalf. During this period before the patenting of Salvarsan, in 1909,
Ehrlich had an average of 8-10 substances patented a year.55 These did not include
every tested chemical produced in the series, but most of those of any significant
therapeutic effect, whether as a germicide of low toxicity or as a febrifuge, were
patented. Salvarsan was developed at the Speyer Haus, controlled by and with the
backing of the government institute, and patented, produced, and marketed
worldwide by Hoechst.56 Salvarsan remained a cause celebre in medicine through the
51 P. Ehrlich, 'Address delivered at the dedication of the Georg-Speyer-Haus' (1906); Collectedpapers,
op. cit., note 14 above, vol. 3, pp. 53-63, on p. 60.
52 Baumler, op. cit., note 2 above, see also P. Ehrlich and K. Shiga, 'Farbentherapeutische Versuche bei
Trypanasomener krenkungen', Berl. klin. Wschr., 1904, 13, 14: 421, 546, 584.
" Ibid., repr. in Collectedpapers, op. cit., note 4 above, vol. 3, pp. 24-9.
54 Ibid. See also Baumler, op. cit., note 2 above, pp. 107-30.
55 Drawn from counts of patents in the U.S. Patent Register, 1906-9.
56 See Hoechst AG, Die Salvarsan-Prozesse, vol. 7, Dokumente aus Hoechster Archiven, 1965.
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First World War. Up to the time when the overseas patents were revoked, it earned
a tremendous amount of money, not to mention the boost it gave the company's
reputation.57
Salvarsan seemed to be the culmination of Ehrlich's programme. It caused him a
great deal of trouble since he was constantly called into court to defend himself
against all kinds of affronts, but even so, to him itjustified the Speyer Haus:
for the first time a new type of therapeutic institution was formed, in which my
dearest thought was realised, by chemical syntheses being applied to the service of
medicine in the most direct way. Whereas, formerly, the substances were offered to
the medical men by the chemist for testing purpose, the conditions could now be
reversed, and the chemotherapist could give the chemist points which led to the
desired recovery of genuine curative substances.58
It is certain that the Hoechst Company saw the Georg Speyer Haus as an
extension of their own laboratory. This is clear from their archives and internal
memoranda. Each change in the research programme or in the staffing ofthe Speyer
Haus laboratory was noted and commented upon. From the company's point of
view, the Institute was a close ally. Far from there being any distrust between
regulating authority and those being regulated, the staff in Frankfurt were seen
almost as part ofthe firm. Informal contact was frequent, and samples and test runs
were often provided by one for the other.59 When Neisser went on an expedition in
1905 to study the spread of syphilis in a monkey colony, he reported back to the
company, which had provided him with chemicals and special preparations, just as
he gathered material for the Institute's syphilis experiments.60 Similarly, when
Wilhelm Kolle, later to head the Institute and the laboratory, was offered the
directorship ofa large new pharmaceutical department at Casella, it was considered
as much a part of Hoechst's business as if he were their employee.6'
Casella also contributed to research at the Georg Speyer Haus, although Ehrlich's
ties with Hoechst precluded the possibility of his rewarding that firm with patents.
Instead he allowed them to use his name in association with some products, and
provided them the valuable publicity of acknowledging their aid and support. The
Institute also received a percentage of the profits as a fee for testing services.62
For the pharmaceutical industry, Ehrlich and his institute were a legitimate part
ofthe nation's commercial development. Just before the outbreak ofthe First World
War, Carl Duisburg, then director ofBayer, summed up his feelings about trends in
the industry by extolling the advantages ofapplied science:
First, we need a fully equipped chemical laboratory, then a pharmacological
institute with a staff of men trained in medicine and chemistry, an abundance of
57 Ibid.
58 Collectedpapers, op. cit., note 14 above.
59 Bdumler, op. cit., note 2 above, pp. 124-5.
60 File on Neisser expedition 1905, Hoechst Archive.
61 Speyer Stiftung Papers, Cassella File, Frankfurt Stadtsarchiv.
62 Ibid. See also T. S. Work, 'The work of Paul Ehrlich and his position in the history of
medical research', Int. Archs allergy appi. Immun., 1954, 5: 98-114.
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animals to experiment upon, and finally-the latest development in this field-a
chemotherapeutic and bacteriological department, equipped according to the ideas
of Paul Ehrlich; all these must be in close connection with one another.63
When William Kolle took over the Institute for Experimental Therapy he
maintained the relationship between Hoechst and the combined laboratories of the
Institute and the Georg Speyer Haus in the post-war period. Their collaborative
functions centered on Salvarsan, where the three bodies saw their interests as being
identical. Much ofthe correspondence concerns the defence of their patents both in
Germany, where they were being copied illegally, and overseas, where numerous
producers had taken advantage of the expropriation of German-held patents to
make their own branded Salvarsan.64
This particular array of institutions, intellectual goals, governmental functions,
political necessities and profit-seeking motives-expertly balanced by Ehrlich-had
wide influence. Within that context the most exciting therapeutics of the age were
developed, by monopolizing the new antitoxins ofthe mid- to late 1890s, and then by
developing and controlling the first widely used chemotherapeutic agents.
Ehrlich's goal, exemplified in the Georg Speyer Haus, was to free physicians from
the threatened grip of chemists and produce specific synthetic agents which could
be targeted at particular pathogens. This project necessarily, and probably
preferentially, had the co-operation of the pharmaceutical industry. With Hoechst,
this co-operation reached its height. Hoechst had already seen the benefits of a
concerted research effort-its lead in diphtheria antitoxin, for which Behring was
responsible, had assured the company that it could best set the standards which it
had a hand in producing. Its success with Pyramidon had indicated early on how
control over a new synthetic product could benefit its business. Long before the
programme to produce an arsenic-based anti-trypanosome, Hoechst had mastered
the uses of patents. It used their powers not only to capitalize on medicines it had
developed and produced, but also to control the flow of information about
developments elsewhere.
From the points of view of the Speyer Haus and the government Institute there
were no problems associated with Hoechst's use of their developments. The
partnership had been built on an understanding that the regulator should work in
close co-operation with the major producer of antitoxins. To support a research
programme of the ambitiousness of Ehrlich's, the backing of the companies was
required. They were needed to finance the work in the first place and to control the
production in a trustworthy way. The patents also had to be owned and defended by
a powerful organization. Ehrlich also needed that power, to be able to control the
vast productivity of his research team. Furthermore, the products of the research
itselfcould not be made available until after the work was finished to the standards
of the laboratory. A strong commercial force was an essential partner for Ehrlich.
63 C. Duisberg, 'German chemical industry', Chem. News, May 1913, 23: 246-7.
64 Salvarsan-Prozesse, op. cit., note 56 above.
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